Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization.

Nakamoto Y, Mizukoshi E, Kitahara M, Arihara F, Sakai Y, Kakinoki K, Fujita Y, Marukawa Y, Arai K, Yamashita T, Mukaida N, Matsushima K, Matsui O, Kaneko S.

Clin Exp Immunol. 2011 Feb;163(2):165-77. doi: 10.1111/j.1365-2249.2010.04246.x. Epub 2010 Nov 19.

2.

[Dendritic cell-based immunotherapy for hepatocellular carcinoma].

Nakamoto Y, Kaneko S.

Gan To Kagaku Ryoho. 2010 Mar;37(3):413-6. Review. Japanese.

PMID:
20332677
3.

[Pre- and/or postoperative adjuvant therapy for hepatocellular carcinoma].

Imaoka S, Sasaki Y.

Nihon Geka Gakkai Zasshi. 1998 Apr;99(4):229-33. Review. Japanese.

PMID:
9642691
4.

Postoperative therapy options for hepatocellular carcinoma.

Zhong JH, Ma L, Li LQ.

Scand J Gastroenterol. 2014 Jun;49(6):649-61. doi: 10.3109/00365521.2014.905626. Epub 2014 Apr 10. Review.

PMID:
24716523
5.

Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application.

Zitvogel L, Lotze MT.

Res Immunol. 1995 Sep-Oct;146(7-8):628-38. Review. No abstract available.

PMID:
8839171

Supplemental Content

Support Center